Study finds no significant impact of ATP on reducing late recurrence of AF

NewsGuard 100/100 Score

Late recurrence of atrial fibrillation (AF) is not reduced in patients whose pulmonary vein isolation (PVI) treatment incorporates the addition of adenosine triphosphate (ATP), according to results of the UNDER-ATP trial.

Results of the trial, presented at ESC Congress 2015 and published simultaneously in The European Heart Journal (to be confirmed), add to the ongoing debate about ATP use in this setting.

The major cause of AF recurrence after PVI has been reported to be electrical reconnection between the left atrium and pulmonary veins, which re-establishes abnormal rhythm, said study investigator Atsushi Kobori, MD, from Kobe City Medical Center General Hospital in Kobe, Japan..

"Radiofrequency ablation around the pulmonary veins can electrically block the connection but sometimes there are hidden gaps," he explained. "ATP is a chemical that can unmask dormant electrical conduction, therefore we used it after PVI to try to identify these gaps."

UNDER-ATP (which stands for UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate) included 2,113 patients (59-68 years) undergoing their first PVI for AF at 19 cardiovascular centres in Japan.

Patients were randomly assigned to conventional PVI  alone (n=1,001), or with the addition of ATP (n=1,112) after PVI to identify any additional problem areas.

In the ATP group (recommended dose 0.4mg/kg), additional ablation was performed if ATP identified extra trouble spots, whereas in the control group neither ATP or additional ablation was used.

After ablation, ambulatory electrocardiograms (ECG) were recorded twice daily for 2 weeks, with 24-hour ECG monitoring at hospital discharge, 6 months, and 1 year.

The primary endpoint of the study was arrhythmias lasting for more than 30 seconds or requiring repeat ablation, hospital admission, cardioversion or antiarrhythmic drugs between 3 months and 1 year post-PVI.

At 1 year there was no significant difference in outcomes between the groups, with 68.7% of the ATP patients and 67.1% of control patients free from AF.

"We found no significant impact of ATP on reducing late recurrences of AF," concluded Dr. Kobori.

Source:

Kobe City Medical Center General Hospital

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows clear benefit from COVID-19 vaccination for heart failure patients